CurrentBlue Cross Blue Shield - OklahomaPolicy CPCPLAB024

Epithelial Cell Cytology in Breast Cancer Risk Assessment

Defines BCBS Oklahoma reimbursement stance and coding for cytologic analysis of epithelial cells from nipple aspiration/ductal lavage/suction used to assess breast cancer risk; applies to providers submitting claims to BCBS OK.

Policy Summary

PayerBlue Cross Blue Shield - Oklahoma

PolicyEpithelial Cell Cytology in Breast Cancer Risk Assessment

Policy CodePolicy CPCPLAB024

Change TypeNew policy

Effective DateNov. 1, 2022

Next Review Date

Key ActionDo not bill for cytologic analysis of epithelial cells from nipple aspirations (including ductal lavage and suction) as these services are not reimbursable.

SourceLink

POLICY UPDATE CHANGES

New policy created.

3procedure codes listed

Nov. 1, 2022plan effective date

1.0policy version

Coverage Determination

Not reimbursable

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Not reimbursable: Cytologic analysis of epithelial cells from nipple aspirations as a technique to assess breast cancer risk and manage patients at high risk of breast cancer is not reimbursable.

Includes techniques of collecting nipple aspiration fluid such as ductal lavage and suction.

Techniques for collecting nipple aspirate fluid, including but not limited to ductal lavage and suction, are excluded from reimbursement by this policy. These collection methods are referenced explicitly as not reimbursable when used to obtain epithelial cells for cytologic assessment related to breast cancer risk.

The policy designates cytologic analysis of epithelial cells from nipple aspirations performed for breast cancer risk assessment as not reimbursable. Claims submitted for this testing are not covered under the payer’s clinical reimbursement criteria.

Policy note — lab management reimbursement criteria

Policy note: BCBSOK has implemented certain lab management reimbursement criteria; not all requirements apply to each product.

Providers are urged to review Plan documents for eligible coverage for services rendered.

Procedure Codes and Coding Notes

Procedure Codes listed in policyCPTNot Covered

88112
88172
88173

Coding notes

Procedure codes (not covered)CPT: 88112, 88172, 88173

Code systemCPT (procedure codes)

Code count3 codes listed in policy

Provider Responsibilities and Billing Guidance

Prior Authorization

Prior Authorization and Coverage

Prior authorization is not applicable for cytologic analysis of nipple aspiration/ductal lavage because this service is not reimbursable. Providers should confirm member coverage by reviewing the applicable plan documents prior to ordering services.

Not reimbursable: Cytologic analysis of epithelial cells from nipple aspirations (including ductal lavage and suction).
Verify member benefits and any product-specific lab management requirements in the member's plan documents.

Documentation Required

Documentation and Coding Expectations

Providers are responsible for accurate and complete documentation of services performed and must submit claims using valid HIPAA-approved code sets. Upon request, BCBSOK may require additional documentation to support medical necessity and correct coding.

Submit claims using appropriate CPT/HCPCS/ICD-10/NDC codes per industry-standard coding guidelines.
Be prepared to supply supporting documentation when requested to substantiate services billed.

Denial Risk

Non‑reimbursable Service — Denial Risk

Claims for cytologic analysis of epithelial cells from nipple aspirations (including ductal lavage and suction) are not reimbursable and may be denied. Billing these services may result in claim denial and no payment.

Do not bill expecting reimbursement for cytologic analysis of nipple aspiration/ductal lavage.
If billed, these services are subject to denial per BCBSOK reimbursement policy.

Note

Additional Provider Actions

If any additional provider actions are required for lab management or specific products, review the member's plan documents and the applicable laboratory management criteria before providing services.

Review product-specific lab management reimbursement criteria in plan documents.
Confirm eligibility and coverage limitations with the payer prior to service delivery.

Services Not Covered

NOT COVERED: Cytologic analysis of epithelial cells from nipple aspirations — including specimens obtained via ductal lavage or suction — for the purpose of assessing breast cancer risk is not covered and is excluded from reimbursement.

Key Definitions

Definition

TermNipple aspiration cytology / nipple aspirate fluid analysis

DefinitionCytologic analysis of epithelial cells from nipple aspirations

Policy stanceNot reimbursable for breast cancer risk assessment

Definition

TermDuctal lavage / suction collection

DefinitionTechniques of collecting nipple aspiration fluid, including ductal lavage and suction

Policy noteThese collection techniques are included in the policy exclusion from reimbursement

Background and Rationale

Nipple aspirate fluid and ductal lavage techniques are methods used to sample epithelial cells from the breast ductal system for cytologic examination. These procedures collect cellular material from the ducts with the intent of identifying atypical or malignant cells as part of breast cancer risk assessment. Although studied as potential risk-assessment tools, the payer does not support reimbursement for the collection procedures or for cytologic analysis of the obtained nipple aspirate specimens for this indication.

Ordering and Product-Specific Requirements

Billing Rule

Ordering requirements — check plan documents

Providers should review the member’s plan documents for product‑specific coverage rules and follow standard provider documentation and coding submission processes when ordering or billing laboratory services.

Plan documents (e.g., Certificates, benefit booklets) govern when they conflict with this policy.
Follow standard claim submission and coding processes and provide requested documentation to support coverage.

Frequency and Limits

Frequency / reuse constraints

Frequency limitNo frequency limits specified in this policy

Product variabilityBCBSOK lab management reimbursement criteria may vary by product; review plan documents for eligible coverage

Ordering/authorization impactProviders should review plan documents prior to seeking coverage or prior authorization

Policy Revision History

2022-11-01Policy establishedLatest

Policy created and implemented as Version 1.0 effective November 1, 2022.